Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "first"

3326 News Found

SS Innovations unveils battlefield surgery drone system and mobile OR platform at SMRSC 2026
Medical Device | April 10, 2026

SS Innovations unveils battlefield surgery drone system and mobile OR platform at SMRSC 2026

The biggest highlight was Project Vimana, a drone-deployed battlefield trauma surgery system engineered to bring life-saving surgical intervention


GSK Pharma shareholders back Ronojit Biswas’ Board, CFO appointment via postal ballot
News | April 09, 2026

GSK Pharma shareholders back Ronojit Biswas’ Board, CFO appointment via postal ballot

Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker


Redcliffe Labs sells Crysta IVF to MMG Group’s Moon Care to sharpen diagnostics play
Healthcare | April 09, 2026

Redcliffe Labs sells Crysta IVF to MMG Group’s Moon Care to sharpen diagnostics play

Divestment marks Redcliffe’s strategic pivot toward preventive and advanced diagnostics; Crysta IVF to continue under existing leadership


University of Leeds launches landmark HALO study on lifelong impact of childhood blood disorders
Hospitals | April 09, 2026

University of Leeds launches landmark HALO study on lifelong impact of childhood blood disorders

Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust


India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters
Drug Approval | April 09, 2026

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga


Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion
News | April 08, 2026

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio


Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7
News | April 08, 2026

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle


IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals
Digitisation | April 08, 2026

IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals

AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17


Alpha Cognition secures key US patent for traumatic brain injury treatment
Biopharma | April 08, 2026

Alpha Cognition secures key US patent for traumatic brain injury treatment

The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL